πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 1,015 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12286479

Treatment with anti-Ξ±4Ξ²7 antibody

Takeda Pharmaceutical Company Limited Β· Granted Tue Apr 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12280029

Methods of treatment of inflammation related conditions using pluripotent anti-inflammator

INSTITUT PASTEUR DE MONTEVIDEO Β· Granted Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12280063

Anti-retroviral therapies and reverse transcriptase inhibitors for treatment of Alzheimer'

SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE Β· Granted Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12275786

Anti-thyroglobulin t cell receptors

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Apr 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12269887

Anti-canine CD16 polypeptides, anti-canine CD64 polypeptides, compositions including same,

Regents of the University of Minnesota Β· Granted Tue Apr 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12269897

Anti-PCSK9 antibodies

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Apr 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12263173

PLK1 inhibitor in combination with anti-angiogenics for treating metastatic cancer

Cardiff Oncology, Inc. Β· Granted Tue Apr 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12263225

Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an o

Dyne Therapeutics, Inc. Β· Granted Tue Apr 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12258401

Anti-CD47 combination therapy

TEVA PHARMACEUTICALS AUSTRALIA PTY LTD Β· Granted Tue Mar 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12258412

Nucleic acid molecules encoding bispecific anti-BCMA x anti-CD3 antibodies

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Mar 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12252544

Anti-CD63 antibodies, conjugates, and uses thereof

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Mar 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12251440

Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Mar 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12251458

Anti-aging preparation for skin and application thereof

SOUTH CHINA NORMAL UNIVERSITY Β· Granted Tue Mar 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12252481

Anti-viral compounds

Aligos Therapeutics, Inc. Β· Granted Tue Mar 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12252746

Anti-CD46 antibodies and methods of use

The Regents of the University of California Β· Granted Tue Mar 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12246064

Method of treating Crohn's disease by administering a triple combination therapy of anti-i

Takeda Pharmaceutical Company Limited Β· Granted Tue Mar 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12239656

Nucleoporins as drug targets for anti-proliferative therapeutics

SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE Β· Granted Tue Mar 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12240902

Anti-TREM2 antibodies and methods of use thereof

DENALI THERAPEUTICS INC. Β· Granted Tue Mar 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12240917

Anti-complement C1s antibodies and uses thereof

Bioverativ USA Inc. Β· Granted Tue Mar 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12234294

Pharmaceutical composition of a humanized anti-CD40 antibody

Kiniksa Pharmaceuticals, GmbH Β· Granted Tue Feb 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12227581

Anti-BCMA single domain antibodies and application thereof

SHENZHEN PREGENE BIOPHARMA CO., LTD. Β· Granted Tue Feb 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12226490

Anti-ROR1 antibody conjugates, compositions comprising anti ROR1 antibody conjugates, and

Sutro Biopharma, Inc. Β· Granted Tue Feb 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12215169

Anti-complement C1s antibodies and uses thereof

Bioverativ USA Inc. Β· Granted Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12209138

Anti-CD38 antibodies

Takeda Pharmaceutical Company Limited Β· Granted Tue Jan 28 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 23 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted